Fangzhou Jianke and Innovent Biologics Forge Strategic Partnership to Unlock the 'AI + Weight Management' Market

On September 10, at the 10th H2H Medical Service Ecosystem Conference hosted by Fangzhou Pharmaceutical, Fangzhou Pharmaceutical (06086.HK), a leading domestic AI-driven chronic disease management enterprise, officially signed a strategic cooperation agreement with Innovent Bio (hereinafter referred to as “Innovent Bio”). Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, and Tan Zaiqiang, Vice President of Retail in the Omni-channel Business Division of Innovent Bio, jointly attended the signing ceremony.

This strategic cooperation aims to integrate Fangzhou Pharmaceutical'sAI+The digital-intelligent service capabilities in the field of chronic disease management and Innovent Bio’s advantages in innovative drug R&D for metabolic diseases, joining hands to build “AITechnology+Innovative Products+"Digital-Intelligence Collaboration Model for 'Precision Services' to Support 'Healthy China'"2030“Contribute innovative strength to the realization of strategic goals.” 

Fangzhou Pharmaceutical and Innovent Bio Officially Sign Strategic Cooperation Agreement

The strategic partnership between Fangzhou Pharmaceutical and Innovent Bio comes at a critical juncture as China’s weight-loss market accelerates its development. According to J.P. Morgan, the market size for weight-loss drugs in China is projected to reach $14.9 billion (approximately RMB 106.2 billion) by 2030. On the policy front, in June 2024, the National Health Commission and 15 other departments formulated and released the “Implementation Plan for the ‘Year of Weight Management’ Campaign.” In April 2025, the National Patriotic Health Campaign Committee issued a notice incorporating initiatives such as healthy weight management into the Healthy China Action.It is evident that weight management has evolved from an individual health behavior into a significant issue in national public health governance.

Faced with a market opportunity valued at hundreds of billions, major pharmaceutical companies are actively positioning themselves to seize the first-mover advantage. In this blue-ocean market, how to build differentiated advantages and explore new solutions and development models has become the focus of industry attention. Against this backdrop, the strategic partnership between Fangzhou Pharmaceutical and Innovent Bio will focus on metabolic diseases such as diabetes and obesity, working together to promote the overall value enhancement in the field of weight management.

Fangzhou Pharmaceutical will rely on itsAITechnological achievements, the H2H smart healthcare new ecosystem, and digital-intelligence industry experience reshape the full-cycle management process for chronic disease patients, creating a personalized, integrated new experience in health management.Leveraging its self-developed Xingshi Medical Large Language Model, the company has completed a full-chain upgrade of its platform ecosystem and launched five AI-powered products: AI Medication Finder, AI Health Manager, AI Doctor’s Assistant, AI Academic Assistant, and AI-Powered Search.

As a distinguished representative of China’s innovative pharmaceutical enterprises, Innovent Bio has grown into a globally leading biopharmaceutical company through over a decade of development, driven by its innovative R&D achievements. The company currently boasts 16 commercialized products, more than 30 pipeline candidates, and a commercialization network covering over 300 cities. Studies have shown that mazdutide, its next-generation weight-loss drug, can significantly reduce body weight while also improving multiple health indicators, including blood pressure, blood lipids, and uric acid levels.^[1]. This innovative drug was also selected as one of the Top 10 Most Anticipated Drugs Globally in 2025.

Building on the strong start of this strategic partnership, both parties will leverage their respective strengths to drive innovative treatment solutions andAIDeep integration of technology-driven digital and intelligent health management, jointly building “AI+A New Service Paradigm in the “Weight Loss” Sector.Specifically, in the field of pharmaceutical care services, leveraging the real-time response capabilities of AI-powered medication assistants, patients with obesity can obtain professional support—including 24/7 online consultations, online medication search, and medication-related Q&A—without waiting, thereby completely breaking the temporal and spatial constraints of traditional pharmaceutical services. In terms of weight management, the AI health steward serves as a round-the-clock health management partner for patients, providing extended services such as personalized medication guidance, service reminders and management, report interpretation, and health education. This approach not only offers psychological reassurance but also reduces decision-making costs, effectively enhancing patients’ health literacy and self-management capabilities.

Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou Pharmaceutical, stated, “We are delighted to enter into a strategic partnership with Innovent Bio. The company has always been committed to enhancing the accessibility of internet-based medical and healthcare services through the application of AI technologies. Innovent Bio’s innovative achievements in the field of metabolic diseases are highly complementary to our digital-intelligent service capabilities. We look forward to exploring, through this collaboration, new models for the deep integration of innovative pharmaceuticals and digital-intelligent health services.”

Looking ahead, Fangzhou Pharmaceutical and Innovent Bio will continue to deepen their exploration of digital and intelligent health management, helping to enhance the service quality and treatment accessibility for chronic disease management in China, and providing more patients with a more efficient, precise, and convenient health management service experience.

[1]Linong Ji,et al.Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight[J].The New England Journal of Medicine.2025